Business
CiRT expanded validation for ICI immunotherapies
CiRT expanded validation for ICI immunotherapies.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n\nOxford BioDynamics Plc\n \nPeer-reviewed study results confirm and expand validation of Oxford BioDynamics' EpiSwitch® CiRT blood test for checkpoint inhibitor immunotherapies\n· Publication in high-impact journal Cancers describes the development and validation of OBD's EpiSwitch CiRT blood test for predicting individual cancer patient's therapeutic response to checkpoint inhibitor immunotherapies\n· Results of the peer-reviewed studies document the expanded validation of CiRT to five widely used checkpoint inhibitors across 280 patients and 14+ broad oncological indications\n· The first-in-class liquid biopsy test demonstrated high accuracy (85%), sensitivity (93%), specificity (82%) to aid physicians in identifying responders\n· CiRT continues to post record monthly orders in the US and is available to physicians at mycirt.com\nOxford, UK - 15 May, 2023 - Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces the publication in the journal Cancers of an expanded validation supporting the use of its EpiSwitch CiRT (Checkpoint inhibitor Response Test) test across the majority of widely used anti-PD-1/L1 checkpoint inhibitor monotherapies.\nOBD's EpiSwitch CiRT is a first-of-its-kind blood test that predicts an individual cancer patient's therapeutic response to immune checkpoint inhibitors (ICIs), providing unique benefits for physicians in treatment planning and navigating complex decisions [1]. Despite pre-screening with currently approved tests, such as tumor PD-L1 expression, typically only 1 in 5 patients see an overall anti-cancer benefit to costly ICIs for most cancers, and many face one or more adverse events [2].\nIn this peer-reviewed study, prospective clinical trials representing 280 treatments with ICIs were used to develop, verify and validate a predictive assay comprising the eight 3D genomic biomarkers used in CiRT. The blood-based biomarker assay achieved high accuracy (85%), sensitivity (93%), specificity (82%), and NPV (97% negative predictive value) across 14+ broad oncological indications, including melanoma, head and neck, lung, pancreas, prostate, liver, colon and breast cancer [3].\nThe work builds on an earlier study pu...